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Autoimmunity develops when self-tolerance mechanisms are failing to protect healthy 
tissue. A sustained reaction to self is generated, which includes the generation of effec-
tor cells and molecules that destroy tissues. A way to restore this intrinsic tolerance 
is through immune modulation that aims at refurbishing this immunologically naïve or 
unresponsive state, thereby decreasing the aberrant immune reaction taking place. One 
major cytokine has been shown to play a pivotal role in several autoimmune diseases 
such as rheumatoid arthritis (RA) and multiple sclerosis (MS): tumor necrosis factor alpha 
(TNFα) modulates the induction and maintenance of an inflammatory process and it 
comes in two variants, soluble TNF (solTNF) and transmembrane bound TNF (tmTNF). 
tmTNF signals via TNFR1 and TNFR2, whereas solTNF signals mainly via TNFR1. TNFR1 
is widely expressed and promotes mainly inflammation and apoptosis. Conversely, 
TNFR2 is restricted mainly to immune and endothelial cells and it is known to activate the 
pro-survival PI3K-Akt/PKB signaling pathway and to sustain regulatory T cells function. 
Anti-TNFα therapies are successfully used to treat diseases such as RA, colitis, and 
psoriasis. However, clinical studies with a non-selective inhibitor of TNFα in MS patients 
had to be halted due to exacerbation of clinical symptoms. One possible explanation for 
this failure is the non-selectivity of the treatment, which avoids TNFR2 stimulation and its 
immune and tissue protective properties. Thus, a receptor-selective modulation of TNFα 
signal pathways provides a novel therapeutic concept that might lead to new insights in 
MS pathology with major implications for its effective treatment.
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inTRODUCTiOn
Multiple sclerosis (MS) affects approximately 2.5 million people worldwide. It is considered as an 
autoimmune disease characterized by white and gray matter lesions in the central nervous system 
(CNS) caused by autoreactive T cells that escaped from central and peripheral tolerance patrolling 
mechanisms. These cells travel along with activated B cells and monocytes to the CNS where they 
infiltrate, starting a synergistic attack against myelin (1). As demyelination is a key feature of MS 
pathology, several myelin proteins have been investigated as targets of these autoreactive lympho-
cytes. It has been shown that myelin basic protein and myelin oligodendrocyte glycoprotein are 
recognized by mature autoreactive T-helper cells in MS patients but also in healthy individuals (2). 
The identification of a major T cell autoantigen in MS is still a matter of controversy. It may be due 
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to technical limitations in autoantibodies’ detection or epitope 
spreading (3). Anyway, the search of pathological anti-myelin 
immune responses is still open-ended.
Currently, the etiology of MS has been investigated from 
another angle that favors the idea that initial pathology occurs 
within the CNS, similarly to other neurodegenerative disorders 
such as Alzheimer’s and Parkinson’s diseases (4). This theory argues 
that degeneration of oligodendrocytes and/or myelin initiates 
pathology by releasing autoantigen, which in turn are responsible 
for the autoimmune, inflammatory response in the organism. 
Of importance, mitochondrial dysfunction (5), ROS production 
(6), misfolding of proteins (7), and release of proapoptotic signals 
(8) are just few of the consequences (9). Myelin-loaded microglia/
macrophages are also largely involved in this pathological process 
(10). They are constantly producing ROS through oxidative burst 
giving rise to mitochondrial dysfunction and proapoptotic sig-
nals release causing oligodendrocytes death and demyelination.
Being it autoimmune or neurodegenerative, the study of the 
nature of this disease is yet mostly descriptive than causative. 
With this limited understanding, the animal models currently 
available seem to mimic only few and separated features of the 
disease, which further restrict our view of the underlying mecha-
nisms causing MS. Even though it seems very difficult to achieve 
a solid and unifying explanation, great efforts have been made 
to develop treatments to reduce the symptomatic incidences in 
MS patients. The available therapeutic strategies are primarily 
focused on suppressing or modulating certain immune functions 
thereby leading to a partial and temporary recovery sometimes 
with major side effects (11). There is still a strong urge for an 
effective treatment that slows down MS disease progression or to 
prevent its development.
This review will focus on the potential value for MS treat-
ment of tumor necrosis factor alpha (TNFα), a major cytokine 
involved in several biological functions. Furthermore, the diffe- 
rent and dual functions of TNFα are specified by the two recep-
tors (TNFR1 and TNFR2) that it activates. Current research 
highlights a great potential of selectively targeting TNF–TNFRs 
signaling with promising immune protective, tissue regenerative, 
and neuroprotective therapeutic properties.
AnTi-TnF THeRAPieS in AUTOiMMUniTY
Self-recognition is an essential biological process that gives rise 
to immune tolerance: a state of indifference or non-reactivity 
toward a substance that would normally be expected to excite 
an immunological response (12). Yet, when the immune system 
erroneously identifies a self-antigen as a danger, it initiates an 
inflammatory response against it. The latter mechanism is defined 
as autoimmunity, which encompasses tissue damage, caused by 
T-cell or antibody reactivity to self. Many inflammatory diseases 
are autoimmune diseases, including rheumatoid arthritis (RA), 
MS, Graves’ disease, type 1 diabetes mellitus, Crohns’ disease, 
and others. Nowadays, they affect 12.5% of the world’s population 
(13) and they can be distinguished based on their primary target 
organ (joints, skin—psoriasis; CNS—MS; intestine—inflamma-
tory bowel disease (IBD); pancreas—type 1 diabetes mellitus). 
For many years, the standard treatment relied on diminishing 
autoimmune pathology with general immunosuppressive agents, 
anti-proliferative drugs, and corticosteroids. Halting the immune 
system has always major and diffuse side effects that increase the 
toxicity of the intervention thereby decreasing its therapeutic 
value. Immunosuppressant drugs are widely used by clinicians 
to reduce inflammatory attacks on tissues but, due to their low 
efficacy, disease-modifying drugs with greater specificity and 
lower toxicity were implemented. Monoclonal antibodies and 
engineered biological products have become now standard 
interventions for several autoimmune diseases, including MS. 
A long standing class of biologics used for many autoimmune 
diseases is TNF blockers which includes infliximab, etanercept, 
adalimumab, PEGylated certolizumab, and golimumab. These 
are the FDA-approved anti-TNF biologics for the treatment of 
Crohn’s disease, ulcerative colitis, RA, ankylosing spondylitis 
(AS), psoriatic arthritis, and plaque psoriasis (14). Even though 
it has been extensively studied, the potential therapeutic value of 
blocking TNF is limited by its partial efficacy in different diseases. 
Anti-TNF treatment is discontinued in 1/3 of RA patients within 
the first year of treatment (15). Around 10–30% of IBD patients 
do not respond to initial treatment while 23–46% lose response 
over time (16). Similarly, 27% of patients with psoriasis discon-
tinue anti-TNF treatment after a year or lose its efficacy over time 
(17). So far, there is little evidence explaining the reasons and risk 
factors for primary or secondary non-response. Therefore, other 
strategies are implemented by clinicians to maintain efficacy with 
acceptable tolerability such as using a different TNF blocker, 
switching class of biologic, dose adjustments, and change in route 
of administration, when possible. Moreover, failure of anti-TNF 
therapies can also be due to development of adverse effects such 
as infections, malignancies, acute infusion and injection reac-
tions, autoimmunity, and cardiovascular effects (18, 19).
In 1999, a clinical trial testing the efficacy of a TNF inhibitor, 
Lenercept, for MS treatment had to be halted due to exacerba-
tions of symptoms when compared to placebo-treated MS pati- 
ents (20). Likewise, there are several clinical reports of RA and 
AS patients treated with TNF blockers that developed CNS dem-
yelination after treatment (21, 22).
Although partially effective in other autoimmune diseases, 
anti-TNF therapies in MS patients seem to worsen pathology and 
clinical symptoms. A possible explanation for this failure is the 
inability of the drug to grant access to the CNS (23). In other 
tissues is rather easy to penetrate and exert a local effect, the brain 
is a privileged site that instead restricts entry to macromolecules 
such as biologics. Furthermore, non-selective TNF inhibitors 
dampen down the active inflammatory response ongoing in 
certain diseases such as RA and IBD. While for these diseases the 
anti-inflammatory effects could be enough for (at least partial) 
recovery, MS treatment requires a more profound reestablishment 
of homeostasis that includes tissue protective and regenerative 
properties. Interestingly, the last two decades of research on TNFα 
signaling showed that the soluble form of TNF (solTNF) triggers 
apoptotic and proinflammatory signals to the cell via TNFR1 while 
the transmembrane form (tmTNF) is able to promote cell survival 
through TNFR2 activation (see Figure 1). The following chapter 
recapitulates the current studies trying to specify and optimize 
selectively targeting TNF–TNFRs within an MS therapeutic frame.
FigURe 1 | Hypothetical working model. TNFα and its receptors regulate major functions of several cell types. This model represents the expected effects of 
selectively modulating TNF–TNFRs signaling. sTNF, soluble TNF; tmTNF, transmembrane TNF; ATROSAB, TNFR1 antagonistic antibody; EHD2-scTNFR2, TNFR2 
agonist; CD8+ T cell, cytotoxic T cells; CD4+ T cells, helper T cells; DC, dendritic cell; BBB, blood–brain barrier; Tregs, regulatory T cells; CNS, central nervous 
system; OPCs, oligodendrocyte’s precursor cells; OLGs, oligodendrocytes; TNFα, tumor necrosis factor alpha.
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TnF–TnFR SignALing: THeRAPeUTiC 
iMPLiCATiOnS FOR MS
Tumor necrosis factor alpha is a pleiotropic cytokine regulating 
many physiological and pathological functions such as cell sur-
vival (24), apoptosis (25), inflammation (26–28), autoimmunity 
(29), demyelination (30), and cancer (31). TNFα is synthesized 
as a transmembrane protein of 26 kDa and forms a stable homo-
trimeric molecule (tmTNF). Proteolytic cleavage of the protein 
via TNFα converting enzyme (TACE/ADAM17) produces a 
17-kDa monomeric protein, a soluble homo-trimeric molecule 
of 51 kDa (solTNF). TNFα signaling is then generated through 
the interaction with two distinct transmembrane receptors, the 
55-kDa TNF receptor type I (TNFR1) and the 75-kDa TNF 
receptor type II (TNFR2). The two TNFα variants display different 
affinities for the two receptors. TNFR1 is activated by both soluble 
and transmembrane forms with higher affinity for solTNF while 
activation of TNFR2 is solely due to tmTNF. Furthermore, the 
two receptors differ in the intracellular pathways that they trigger 
leading to various cellular responses (32–34). TNFR1 has been 
described as stimulator of effector caspase-mediated apoptosis 
(35, 36), while TNFR2 promotes cell survival through PI3K-Akt/
PKB signaling pathway (37, 38). However, TNFR1 activation may 
also prevent TNF-induced apoptosis by activating the classical 
NF-κB pathway (39) and receptor-interacting protein 1 (RIP1) 
ubiquitination (40). Upon TNFR1 stimulation, the intracellular 
death domain (DD) recruits RIP1 and TNFR-associated death 
domain (TRADD). TRADD engages TNFR-associated factor 2 
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(TRAF2), inhibitor of apoptosis protein 1 (cIAP1) and inhibitor 
of apoptosis protein 2 (cIAP2) thereby leading to the formation 
of complex I (41). RIP1 ubiquitination and complex I activation 
later stimulates catalytic IκB kinase (IKK) complex, which favors 
the activation of NF-κB pathway (42). If this signaling fails, com-
plex II will trigger caspase 8-mediated apoptosis upon TNFR1 
ligand binding (43). Importantly, the initiation of this apoptotic 
process heavily relies on the levels of the inhibitory protein (cFLIP). 
The more NF-κB is activated by complex I, the more cFLIP will 
be available to inhibit caspase-mediated apoptosis (44).
In addition, it was shown that TNFRs cross talk intracellu- 
larly giving rise to TNFR1-induced cell survival and TNFR2-
induced apoptosis (33). In contrast with TNFR1, TNFR2 does 
not contain a DD but it is still capable of inducing apoptosis upon 
its activation (45). A common intracellular molecule family in 
the TNFα signaling cascade is TRAFs, which are recruited by both 
TNFRs complexes. In CD30 and CD40 cells, TNFR2 stimulation 
might lead to TRAF2 degradation, which results in caspase 8 
activation and eventually apoptosis (46). TRAF2 is also an im- 
portant regulator of cell survival through TNFR1-mediated acti-
vation of C-Jun and NF-κB. In vitro studies showed that NF-κB 
activation leads to production of TRAF1, which blocks TNFR2-
mediated degradation of TRAF2 (47).
Another distinctive feature of these two receptors is their 
differential expression in different tissues. While TNFR1 is ubiq-
uitously expressed, TNFR2 can be found mainly on endothelial 
cells, various immune cells, and certain CNS cells (48).
All these peculiar features enable such a complex cytokine to 
have major, sometimes conflicting, effects depending on its form, 
the receptor that it triggers and the cell type on which it may 
act (see Figure 1). Because of this pleiotropic effect, the function 
of TNFα will depend on the ratio of co-expression of its recep-
tors which will shift the balance between cellular survival and 
apoptosis.
The following sections will highlight the beneficial proper-
ties of targeting selectively TNFRs’ signaling pathway found in 
in vitro and in vivo models of MS (see Table 1). This may help to 
further elucidate the therapeutic value of TNFα in the treatment 
of MS and other autoimmune diseases.
SeLeCTive TARgeTing OF TnFRs: 
iMMUne PROTeCTiOn PROPeRTieS
Growing evidence suggest that proinflammatory factors are 
intertwined with a complex resolution program of inflammation 
after few hours an inflammatory response begins (54–56). In a 
coculture experiment with murine CD4+CD25+FoxP3+ regu-
latory T  cells (Tregs) and CD4+CD25− effector T  cells (Teffs), 
short-term exposure to TNFα promotes Teffs expansion while 
a more prolonged treatment favors proliferation and activation 
of Tregs (57). Moreover, TNFR2−/− mice show normal pool of 
Tregs but, when stimulated with septic challenge, they fail to 
expand. This suggests that TNFα might have a proinflammatory 
action in the early phases of inflammation through Teffs to leave 
then Tregs to re-establish homeostatic balance through TNFR2 
signaling. Similar evidence comes from leukocytes isolated from 
RA patients on anti-TNF medications (58). Adalimumab, an anti-
TNF antibody, but not the solTNFR2 Etanercept, promotes the 
interaction between monocytes and Tregs leading to expansion 
of FoxP3+ Tregs and suppression of Th17  cells through IL-2/ 
STAT5 pathway. This effect is caused by adalimumab binding to 
tmTNF on monocytes, which is able to enhance both expression 
of tmTNF and its binding to TNFR2 on Tregs. Additionally, 
increased IL-17 production in TNFR2-deficient T cells is prev-
ented by exogenous IL-2 showing that tmTNF–TNFR2 signaling 
suppresses Th17 differentiation by promoting IL-2 expression (59). 
Furthermore, an in vivo EAE study with TNFRs−/− mice showed 
a reduction of clinical symptoms, demyelination score, CD3+ T cell 
infiltrates, and activated microglia/macrophages in TNFR1−/− 
mice. On the contrary, lacking TNFR2 seems to worsen EAE 
disease course. In the same study, EAE was induced in normal 
C57BL/6 to investigate the effect of antibody-mediated TNFR1 
inhibition. These results show attenuated EAE severity and de- 
layed the onset of disease in the treated group mainly through 
decreased demyelination score and neuronal loss while there is 
only a mild reduction in immune infiltrates into the CNS (60). If 
silencing TNFR1 is not enough, activation of TNFR2 in mouse 
microglia culture promotes expression of anti-inflammatory and 
neuroprotective genes as granulocyte colony-stimulating factor, 
adrenomedullin, IL-10, and IFN-γ (61). Specifically, conditional 
knockout of microglial TNFR2 reveals earlier EAE onset by 
means of increased number of infiltrates, T cell activation, and 
demyelination scores. On the other hand, ablation of microglial/
macrophage TNFR2 leads to EAE suppression (62). This experi-
ment further expands our knowledge of TNFα functions on its 
receptors: TNFR2 has dual roles depending on its location in 
central or peripheral myeloid cells as much as solTNF and tmTNF 
have detrimental or protective properties, respectively.
SeLeCTive TARgeTing OF TnFRs: 
TiSSUe RegeneRATiOn PROPeRTieS
A crucial pathological hallmark of MS is white matter lesions 
caused by axonal demyelination. An effective pharmacological 
intervention for this disease requires tissue regenerative proper-
ties to counteract tissue damage at the lesion site. In vitro studies 
reveal that TNFR2 activation protects oligodendrocyte’s proge- 
nitor cells (OPCs) from oxidative stress (63). OPCs are increa-
singly being studied in MS research as they are shown to be 
essential to the remyelination process (64). The beneficial effect of 
TNFR2 seems to continue in later stages of development of these 
critical cells. In a primary coculture setup, maturation of oligo-
dendrocytes into myelinating cells appears to be boosted through 
astrocyte-specific TNFR2 stimulation (65). In 2001, an impor-
tant in vivo study investigated the different role of TNFRs in the 
cuprizone model for demyelination (see Table 1) in mice lacking 
either TNFα or one its receptors (66). In this study, the absence 
of TNFα delays the remyelination process due to reduction of 
pro liferating OPCs and mature oligodendrocytes when com-
pared to wild type mice. Interestingly, similar effects are found 
in mice lacking TNFR2, but not TNFR1, underling a substantial 
role of TNFR2 in promoting oligodendrocytes proliferation and 
TAbLe 1 | Animal models to investigate pharmacological interventions for multiple sclerosis (MS).
Models Species induction Mechanism of action effect on 
physiology






Immunization Autoimmune reaction vs. 
myelin protein
T cell dysfunction Autoimmunity To study the anti-inflammatory effects against  




Rodents Toxic Unknown. Iron chelator 







To study the (re)generative properties on myelin 
components, OPCs and OLGs
NBM lesion 
model (51)
Rodents IC injections of 
NMDA





To study the neuroprotective properties on axonal 
loss, apoptosis, mt dysfunction and  
signal transmission
Selectively targeting TNFR1 and/or TNFR2 has promising therapeutic potential. The animal models available nowadays have several limitations (52, 53) that require the study of 
different pathological hallmarks of disease in different models. Here, we show three widely used animal models that give an almost exhaustive overview of MS pathology when taken 
altogether.
EAE, experimental autoimmune encephalomyelitis; NBM, nucleus basalis of Meynert; IC, intracerebral; NMDA, N-methyl-d-aspartate acid; MT, mitochondrial; OLG, oligodendrocyte; 
CC, corpus callosum; OPC, oligodendrocytes precursors cell; Tregs, regulatory T cell.
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regeneration. In this vein, inhibition of solTNF shows that tmTNF 
increases axon preservation and improves myelin compaction in 
an EAE mouse model for MS (67). In the same study, myelin-
specific genes and increased number of OPCs are found upon 
tmTNF treatment. A recent EAE study with conditional knockout 
mice highlights that TNFR2 specifically on oligodendrocytes 
drives their differentiation and remyelination (68). Furthermore, 
treatment with XPro1595, a selective solTNF inhibitor, in a cup-
rizone mouse model (see Table 1) shows faster remyelination due 
to improved myelin phagocytosis by microglia (69).
SeLeCTive TARgeTing OF TnFRs: 
neUROPROTeCTiOn PROPeRTieS
In the progressive stages of MS, axonal loss and neurodegene-
ration seem to take over, at least partially, inflammation as main 
pathological hallmarks (70). Several in  vitro studies underline 
the potential neuroprotective effect of selective targeting of 
TNFRs. In a human dopaminergic neuronal cell line (LUHMES), 
TNFR2 stimulation of the PI3K-PKB/Akt pro-survival pathway 
rescues neurons from oxidative stress-induced cell death (71). 
Furthermore, similar results were found in an in vitro model of 
glutamate-induced excitotoxicity in primary cortical neurons. 
TNFR2, and not TNFR1, induces persistent PI3K PKB/Akt-
mediated NF-κB activation leading to neuroprotection, which is 
enhanced by N-methyl-d-aspartate receptor co-stimulation (37). 
Using the same in vitro model, another study shows that activa-
tion of TNFR2 signaling pathway mediated lovastatin-induced 
neuroprotection against glutamate excitotoxicity (72). Statins 
are widely prescribed in clinical practice for lowering cholesterol 
levels. Nonetheless, a specific statin, called Simvastatin, has 
been shown to be effective in decreasing whole-brain atrophy 
in patients with secondary progressive MS in a phase II trial 
(73). The neuroprotective effect of TNFR2 was also found in an 
in vivo model using TNFR1−/− and TNFR2−/− mice. After retinal 
ischemia, TNFR1 deficiency leads to strong decrease in neuronal 
death while absence of TNFR2 leads to enhanced neurodegen-
eration (36). Another in  vivo model using genetic ablation of 
solTNF shows neuroprotection against focal cerebral ischemia (74). 
Interestingly, a recent study reveals that the neuroprotective and 
anti-inflammatory effects found by antagonizing TNFR1 in the 
nucleus basalis lesion (NBM) model (see Table 1) is enhanced 
through TNFR2 signaling (75).
FUTURe PeRSPeCTiveS
Due to contradicting results concerning TNFα and TNFR signa-
ling in neurodegenerative diseases in the late 90s, major advances 
have been made in recent years in understanding the biology of 
TNF–TNFRs signaling in health and disease. This review high-
lighted the potential therapeutic value of this target, specifically 
within MS pathology. Of importance, the available MS treat- 
ments are focused on limiting the burden and occurrence of 
autoreactive peripheral immune cells. We can see them as drugs 
boosting the immune system’s resistance toward an insult against 
self-tissue. Obviously, this leads to a temporary effect of the treat-
ment, which is followed by a partial decrease in symptoms, mainly 
in patients with relapsing-remitting MS. Moreover, most of these 
drugs are not able to slow down disease progression. Recently, 
several immunologists and evolutionary ecologists introduced 
the concept of disease tolerance as a defense mechanism against 
infectious agents (76–78). In flies (79), rodents (80), and humans 
(81) studies, modulating disease tolerance resulted in protection 
against several types of infection and restored homeostasis (82). 
As in different patrolling mechanisms, attack is not always the 
best defense mechanism: damage control is as important as 
pathogen control. Within autoimmunity, dysregulated disease 
tolerance can be seen as a failure of the immune system to control 
tissue damage caused by autoreactive immune cells. Interestingly, 
selective modulation of TNFRs triggers a variety of protective 
and pro-survival properties, which in turn are positively affecting 
the pathological milieu derived from autoreactive lymphocytes. 
Breaking the vicious circle of chronic inflammation and protect 
tissue against further damage are essential features for a thera-
peutic agent that aims at restoring proper immune functions and 
general homeostasis.
Nevertheless, some challenges need to be addressed to fur-
ther elucidate the potential of this treatment target. As briefly 
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mentioned above, activating TNFR2 in peripheral or central 
myeloid cells resulted in opposing therapeutic effects (62) under-
ling the need for a pharmacological approach that minimizes 
peripheral immune activation. However, blood–brain barrier 
(BBB) permeability of these compounds might be an obstacle 
to overcome in order to reach all beneficial effects of this target. 
In the past decade, great progress has been made in developing 
nanoparticles (83, 84) and cell-specific drug carriers (85) through 
the BBB, giving a promising perspective for CNS diseases (86).
To conclude, selective modulation of TNFRs through TNFR2 
activation and/or TNFR1 silencing has great therapeutic potential 
in terms of immune, tissue, and neuroprotective properties, espe-
cially for MS treatment.
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